Guselkumab Leads to Rapid Ulcerative Colitis Symptom Improvement
Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.